Emerging Pathogens, Vaccine and Breakthrough Infection News and Medical Cases
No significant difference in hospitalization between immunized and non-immunized found for SARS-CoV-2 Beta variant
Get link
Facebook
X
Pinterest
Email
Other Apps
A study of vaccinated and unvaccinated residents of Bangladesh observed that ChAdOx1 could not prevent the new infection or severe COVID-19 disease outcome with single dose when infections were mostly caused by B.1.351 (the Beta) variants of SARS-CoV2.
About 39% (n = 42) of the respondents were infected after the COVID-19 vaccination. The first dose of ChAdOx1 nCoV-19 vaccine was received by 40 (37.0%) cases and both doses were completed by only 2 (2%) cases. The average duration between vaccination (partially or completely immunized) and COVID 19 diagnosis was 32 (±17) days.
The hospitalization rate of comorbid patients was 23.5% among the immunized and 24.1% among the nonimmunized groups. There was no significant difference in duration of hospitalization either (p=0.78).
Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh
Al-Emran HM, Hasan MS, Setu MA, Rahman MS, Alam AR, Sarkar SL, Islam MT, Islam MR, Rahman MM, Islam OK, Jahid IK. Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. Journal of Infection and Public Health. 2021 Dec 7.
As we venture into the end of summer, there’s no denying that COVID-19 is making its move again. Covid waves always follow a seasonal pattern - two waves per year: winter and summer or fall. So far, the smallest (not in terms of deadliness though, just the number of infected) wave hit during the winter of 2020-2021, while the Omicron surge of 2021-2022 took the crown for the biggest wave. Last year was a bit of a wild card, with the summer/fall wave being slightly taller than the winter one. However, so far, this year hasn’t had much of a summer/fall wave (yet) but hold on tight because things are looking a little more intense as we approach the winter. From December 2024 to February 2025, we experienced what could be called "Wave X," a quieter episode compared to earlier waves, but it still made its presence felt. Fast forward to August 2025, and we’re beginning to see the rise of the next wave—a little like what we saw in 2023 and 2024. According to Mike Hoerger’s post on ...
From wild type to Alpha (B.1.1.7), Delta (B.1.617.2), Omicron BA.1, BA.2, BA.5, BQ.1/BA.2.75, XBB, JN.1, FLiRT variants and now XEC and LP.8.1 (BA.2.86.1), the virus keeps evolving, continuously demonstrating its ability to adapt and mutate. As we enter the tenth wave of COVID-19 in the U.S, the XEC variant has emerged as the dominant strain - in line with expectations. It could be " a weak leading variant " but will it be a " very muted holiday wave relative to all prior years , due to weak evolution and large summer numbers"? Until recently in the US KP.3.1.1 was dominating wastewater samples and accounting for a considerable proportion of infections. Looking at the growth advantages of variants over the last year led to predictions of significantly lower impact than JN.1 that "XEC should only modestly bump what the winter wave would be without any new variant" by one of COVID forecasters . But other variants are also gaining traction. The off...
Post-Vaccination IgG4 and IgG2 Class Switching is linked to Increased Risk of SARS-CoV-2 Infections A new study published in Infectious Disease Practice has revealed a concerning correlation between the class switching of antibodies after COVID-19 mRNA booster vaccinations and a heightened risk of breakthrough infections. Specifically, the study found that elevated levels of IgG4 and IgG2 antibodies, which increase significantly following the third mRNA dose, are linked to an increased risk of symptomatic SARS-CoV-2 infections. The study analyzed a longitudinal subset of 83 healthcare workers who received three doses of the COVID-19 vaccine. Additionally, they included 66 healthcare workers from the same cohorts who were analyzed at a specific timepoint (T9) corresponding to May 2022, four months after the first booster vaccination. The study, conducted by a team of researchers from Spain, tracked the immune responses of healthcare workers over nearly three years. They observed ...
Comments
Post a Comment